Cargando…

Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population‐Based Study

BACKGROUND: Direct oral anticoagulants (DOACs) are noninferior to warfarin for stroke prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and death in incident AF, stratified by anticoagulation status and type, and the temporal trends of oral anticoagulation p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Amy Y. X., Malo, Shaun, Svenson, Lawrence W., Wilton, Stephen B., Hill, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721787/ https://www.ncbi.nlm.nih.gov/pubmed/29080863 http://dx.doi.org/10.1161/JAHA.117.007129

Ejemplares similares

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation
por: Simon, Tracey G., et al.
Publicado: (2023)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Bonanad, Clara, et al.
Publicado: (2021)

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
por: Jansson, M., et al.
Publicado: (2023)

Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014)

International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Anticoagulants in Older Patients with Nonvalvular Atrial Fibrillation after Intracranial Hemorrhage
por: Perreault, Sylvie, et al.
Publicado: (2019)

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

Nine‐year trend of oral anticoagulant use in patients with embolic stroke due to nonvalvular atrial fibrillation
por: Asahina, Chisa, et al.
Publicado: (2020)

Detecting Patients With Nonvalvular Atrial Fibrillation and Atrial Flutter in the Canadian Primary Care Sentinel Surveillance Network: First Steps
por: Queenan, John A., et al.
Publicado: (2020)

Whether Warfarin Therapy is Associated with Damage on Renal Function in Chinese Patients with Nonvalvular Atrial Fibrillation
por: Kong, Yu, et al.
Publicado: (2016)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies
por: Wang, Yimin Pearl, et al.
Publicado: (2020)

How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
por: Schaefer, Jordan K., et al.
Publicado: (2015)

Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation
por: Kim, Young Dae, et al.
Publicado: (2015)

The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
por: Zheng, Huan Jie, et al.
Publicado: (2017)

Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study
por: Van Ganse, Eric, et al.
Publicado: (2020)

Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients
por: Deitelzweig, Steven, et al.
Publicado: (2019)

Current Anticoagulant Usage Patterns and Determinants in Korean Patients with Nonvalvular Atrial Fibrillation
por: Ha, Hyun Su, et al.
Publicado: (2020)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer
por: Potter, Adam S., et al.
Publicado: (2022)

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
por: Toyoda, Kazunori, et al.
Publicado: (2015)

Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
por: Zhou, Xue, et al.
Publicado: (2020)

The differences of atrial thrombus locations and variable response to anticoagulation in nonvalvular atrial fibrillation with ventricular cardiomyopathy
por: Zhang, Hao, et al.
Publicado: (2020)

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
por: Reddy, Vivek Y., et al.
Publicado: (2018)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
por: Watanabe, Tetsuya, et al.
Publicado: (2016)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
por: Chen, Nemin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oqsupqvq50qabvs31f2eo1vbko